Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 7, 2004, Pages 388-394

  Fittkau, Marina ^a   Voigt, Wieland ^a   Holzhausen, Hans Jürgen ^a   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

CPT 11; Diarrhea; Intestinal peptidases; Perfusion; Saccharic acid 1.4 lactone

Indexed keywords

BETA GLUCURONIDASE; ENZYME INHIBITOR; IRINOTECAN; PEPTIDASE; SACCHAROLACTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED DISEASE; ENZYME ACTIVITY; ENZYME RELEASE; EVALUATION; FEMALE; HISTOPATHOLOGY; INTESTINE CRYPT; INTESTINE INJURY; INTESTINE MUCOSA; INTESTINE VILLUS; JEJUNUM; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPECIES COMPARISON; TISSUE FIXATION; TISSUE SECTION;

EID: 3843135145     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0557-8     Document Type: Article

References (48)

1. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449
2. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C (2002) CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94:641-646
3. Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y (2002) Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 24:111-116
4. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697-702
5. Bartlett GR (1959) Phosphorus assay in column chromatography. J Biol Chem 234:466-468
6. Bleiberg H, Cvitkovic E (1996) Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 32A [Suppl 3]:S18-S23
7. Brunelle FM, Verbeeck RK (1997) Conjugation-deconjugation cycling of diflunisal via β-glucuronidase catalyzed hydrolysis of its acyl glucuronide in the rat. Life Sci 60:2013-2021
8. Cao S, Black JD, Troutt AB, Rustum YM (1998) Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58:3270-3274
9. Fittkau M, Gerlach R, Schmoll HJ (2001a) Protective effect of oral phosphatidylcholine on radiation-induced release of intestinal peptidases in rats. J Cancer Res Clin Oncol 127:444-448
10. Fittkau M, Grothey A, Gerlach R, Schmoll HJ (2001b) A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. J Cancer Res Clin Oncol 127:96-100
11. Fittkau M, Gerlach R, Schmoll HJ (2002) Phosphatidylcholine does not protect rats against 5-fluorouracil/folinic acid-induced damage of the intestinal luminal mucosa. J Cancer Res Clin Oncol 128:80-84
12. Gandia D, Abigerges D, Armand JP, Chabot G, Da Costa L, De Forni M, Mathieu-Boue A, Herait P (1993) CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11:196-197
13. Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J (1997) Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 76:952-962
14. Glässer D, Kleine R (1962) Beitrag zur Eiweissbestimmung in stark verdünnten Lösungen. Pharm 17:32-36
15. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ (1997) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502-1510
16. Hecht JR (1998) Gastrointestinal toxicity of irinotecan. Oncology (Huntingt) 12 [8 Suppl 6]:72-78
17. Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y, Bouscarel B (2002) Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62:179-187
18. Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87:1876-1883
19. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11) Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854
20. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1720
21. Kaneda N, Kurita A, Hosokawa Y, Yokokura T, Awazu S (1997) Intravenous administration of irinotecan elevates the blood β-glucuronidase activity in rats. Cancer Res 57:5305-308
22. Kase Y, Hayakawa T, Togashi Y, Kamataki T (1997) Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn J Pharmacol 75:399-405
23. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-191
24. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJ (2001) Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7:1136-1141
25. Küllertz G, Boigk J (1986) Dipeptidylpeptidase IV-Aktivität in Serum und Synovia bei Patienten mit rheumatoider Arthritis. Z Rheumatol 45:52-6
26. Lavrenkov K, Man S, Mermershtain W, Cohen Y (2002) Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer. J Chemother 14:84-87
27. Minagawa Y, Kigawa J, Itamochi H, Terakawa N (2001) The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer. Hum Cell 14:237-243
28. Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K (2003) Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51:403-406
29. Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, Kamataki T (1993) Inhibition of β-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 23:5-10
30. Okamoto R, Takano H, Okamura T, Park JS, Tanimoto K, Sekikawa T, Yamamoto W, Sparreboom A, Verweij J, Nishiyama M (2002) O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 93:93-102
31. Pham-Huy C, Sahui-Gnassi A, Saada V, Gramond JP, Galons H, Ellouk-Achard S, Levresse V, Fompeydie D, Claude JR (1994) Microassay of propranolol enantiomers and conjugates in human plasma and urine by high-performance liquid chromatography after chiral derivatization for pharmacokinetic study. J Pharm Biomed Anal 12:1189-1198
32. Potten CS, Wilson JW, Booth C (1997) Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells 15:82-93
33. Pro B, Lozano R, Ajani JA (2001) Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs 19:341-343
34. Ratain MJ (2002) Irinotecan Dosing: Does the CPT in CPT-11 stand for "Can't predict toxicity"? J Clin Oncol 20:7-8
35. Rivory LP, Bowles MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103-1111
36. Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI et al (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204
37. Sato M, Ando M, Minami H, Ando Y, Ando M, Yamamoto M, Sakai S, Watanabe A, Ikeda T, Sekido Y, Saka H, Shimokata K, Hasegawa Y (2001) Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. Cancer Chemother Pharmacol 48:481-487
38. Shinohara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ (1998) Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. Clin Cancer Res 4:2053-2063
39. Shinohara H, Killion JJ, Bucana CD, Yano S, Fidler IJ (1999) Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. Clin Cancer Res 5:2148-2156
40. Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A (2002) Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Onkologie 25:60-63
41. Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T (1995) Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn Cancer Res 86:978-984
42. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752-3757
43. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1998) Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280-286
44. Tarazona JV, Sanz F (1990) Toxicity of fractions obtained from the legume species Astragalus lusitanicus Lam. lusitanicus. Toxicon 28:235-237
45. Van Cutsem E, Douillard JY, Kohne CH (2001) Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 345:1351-1352
46. Voigt W, Fittkau M, Kopinsky P, Simon H, Holzhausen HJ, Schmoll HJ (2001) Change of histological and apoptotic patterns in the small intestine of rats after CPT-11 treatment. Onkologie 24:202
47. Yamamoto W, Verweij J, de Bruijn P, de Jonge MJ, Takano H, Nishiyama M, Kurihara M, Sparreboom A (2001) Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs 12:419-432
48. Yoshida M, Boku N, Ohtsu A, Muto M, Nagashima F, Yoshida S (2001) Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer 4:144-1449